The vice president and head of Alzheimer’s Disease, Dementia, and Movement Disorders in Late Stage Clinical Development at Biogen spoke about the upcoming TANGO II trial in Alzheimer disease.
Samantha Budd Haeberlein, PhD
Advertisement
Articles by Samantha Budd Haeberlein, PhD
Advertisement
Latest Updated Articles
Samantha Budd Haeberlein, PhD: The TANGO II Trial of BIIB092Published: August 12th 2018 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS
2
FDA Issues Complete Response Letter for Spinocerebellar Ataxia Agent Troriluzole
3
Dental Caries and Periodontal Disease Increase Ischemic Stroke Risk, Study Shows
4
Therapeutic Promise and Mechanism of DYNE-101 to Treat Myotonic Dystrophy: Doug Kerr, MD, PhD
5
